Showing results (441-450 of 733) with videos related to

Sort By:
Pageof 74
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Cancer Discovery|January 11, 2017
APC/C Dysfunction Limits Excessive Cancer Chromosomal InstabilityLaurent Sansregret, James O Patterson, Sally Dewhurst, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2014
89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patientsSietske B M Gaykema, Carolien P Schröder, Joanna Vitfell-Rasmussen, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Plos Medicine|December 7, 2016
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineGerald Goh, Ramona Schmid, Kelly Guiver, et al.
Cancers|May 14, 2022
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced MelanomaKrisztian Homicsko, Reinhard Dummer, Christoph Hoeller, et al.
JCO Precision Oncology|February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM StudyMatthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
Pageof 74